Phase 2 N=10 RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia
Male Infertility, Azoospermia
Primary: Total Motile Sperm — 8; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 Investigating the Physiological Effects of Weight Loss on Male Fertility
Male Infertility · Obesity · Weight Loss
Primary: Sperm Concentration — 53.6; 58.5; 20.1; 15 million sperms/mL
Phase 2 N=171 Males, Antioxidants, and Infertility Trial
Male Infertility
Primary: Live Birth Rate — 15.3; 22.1 percentage of live births
N/A N=114 Impact of DNA Fragmentation in Sperm on Pregnancy Outcome After Intra-uterine Insemination in a Spontaneous Cycle
Infertility Unexplained · Infertility, Male · DNA Damage
Primary: DNA Fragmentation as a Predictor of Live Birth Rate — 32 Participants — p=0.04
Phase 2 N=20 RA-2 13-cis Retinoic Acid (Isotretinoin)
Male Infertility · Klinefelter's Syndrome · Y-chromosome Microdeletions
Primary: Millions of Sperm Per Ejaculate — 2.5; 3.8 Millions of sperm per ejaculate
N/A N=35 SSRI Effects on Semen Parameters in Men
Healthy
Primary: Semen Volume — 2.55 mL
Phase 2 N=33 The Effect and Safety of Lisinopril in Non-hypertensive Men With Infertility From Low Sperm Count
Oligospermia
Primary: Changes From Baseline in the Seminal Fluid Characteristics Throughout the Study — 3.47; 3.20 ml
Phase 2 N=69 Impact of Duloxetine on Male Fertility
Infertility, Male · Depression
Primary: Number of Participants With Abnormal Sperm DNA Fragmentation at 6 Weeks — 0; 2 Participants
Phase 2 N=40 ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
Healthy Males
Primary: Intratesticular Testosterone (IT-T) Level — 14; 3.7; 1.7; 18.4 ng/mL — p=<0.05
Phase 2 N=40 HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone
Healthy Males
Primary: Serum Testosterone (T) — 0.43; 1.5; 3.7; 8.4 nmol/liter — p=<0.05
N/A N=241 Prednisolone Improves IVF Outcomes in Men With Anti-sperm Antibodies
Reproductive Sterility
Primary: Number of Control and Treated Participants With Successful Live Births Following Conventional IVF or ICSI Cycles — 18; 13; 8; 9 participants
Phase 2 N=20 Atrasentan Spermatogenesis and Testicular Function
Nephropathy · Diabetes
Primary: Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26 — 23.5 percentage of participants
N/A N=10 HOP-2A - Intratesticular Hormone Levels
Healthy · Male Infertility · Prostate Disease
Primary: Intratesticular Hormones in Normal Men — 486; 3.0; 3.7; 0.20 ng/mL
Phase 2 N=17 To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
Secondary Hypogonadism
Primary: Sperm Concentration — 0.54; 72.8; 3.00; 182.6 millions sperm/mL — p=0.118
N/A N=80 Assessment of TetraSOD® Efficacy to Improve Semen Parameters in Men With Idiopathic Infertility
Infertility, Male
Primary: Sperm Progressive Motility — 19.62; 25.11 percentage
N/A N=2,370 Folic Acid and Zinc Supplementation Trial (FAZST)
Pregnancy · Live Birth · Spontaneous Abortion
Primary: Live Birth — 404; 416; 97; 91 Participants
N/A N=386 Sperm Selection by Microfluidic Separation Improves Embryo Quality
Sperm DNA Fragmentation · Embryo Quality · Fertility Disorders
Primary: Day 3 High Quality Embryo Percentage — 68; 66 percentage of high quality embryos
N/A N=178 Sexual Function and Wellbeing in Males With Rectal Cancer
Rectal Cancer
Primary: Change in Serum Testosterone Levels Between Baseline and After Preoperative Radiotherapy. — 11.3; 11.9; 9.3 nmol/L — p=0.014
Phase 3 N=18 A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)
Hypogonadism · Hypogonadotropic Hypogonadism
Primary: Change From Baseline in Log-Transformed Testicular Volume at Week 52 — 2.3 Fold change
N/A N=52 Fertility Preservation in Male AYA With Cancer
Infertility, Male
Primary: Fertility Preservation (FP) Uptake — 10; 9 Participants — p==.64
Phase 3 N=379 Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility
Infertility, Female
Primary: Rate of Good Birth Outcomes — 23; 29 Participants — p=0.404
Phase 2 N=76 A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels
Ejaculatory Dysfunction · Hypogonadism
Primary: Change From Baseline in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Ejaculatory Function Score at 16 Weeks — 3.61; 2.95 units…
Phase 2 N=26 A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
Tuberculosis, Pulmonary · Tuberculosis, Multidrug-Resistant · Tuberculosis, MDR
Primary: Change Form Baseline Total Sperm Count — 20 10^6 sperm cells/ejaculate
Phase 4 N=60 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters
Hypogonadism, Male
Primary: Change in Testosterone Levels From Baseline to 27 Weeks — 652 ng/dL
Phase 4 N=59 A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls
Cytomegalovirus Infections
Primary: Change in Sperm Density From Baseline to the End of Treatment (EOT) — -9.770; 30.396 mil/mL — p=0.0075
Phase 1 N=99 Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men
Contraception
Primary: The Number of Men Who Have Suppression of Sperm Production ≤1Million/mL Million/mL When Using a Daily Regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel…
Phase 4 N=181 Study Evaluating the Effects of Avanafil on Semen Parameters
Erectile Dysfunction
Primary: Percentage of Subjects With a Greater Than or Equal to 50% Decrease in Sperm Concentration From Baseline to Week 26 — 1.5; 14.5 percentage of participants
Phase 2 N=24 Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function
Hypogonadism, Male
Primary: IIEF (International Index of Erectile Function) Score - Screen — 34; 43; 57; 41 score on a scale
Phase 3 N=32 PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue
Healthy
Primary: Prostate-specific Antigen (PSA) — 0.8; 0.9; 0.7; 0.4 ng/mL
N/A N=739 Impact of Sperm DNA Integrity on In Vitro Cycles
Male Infertility · Unexplained Infertility · Abortion, Habitual
Primary: Pregnancy — 67; 80 participants